By Chris Wack
Gritstone Bio is pushing back the launch of its Phase 2b head-to-head trial of its next-generation Covid-19 vaccine to the fall of 2024 rather than the first quarter of 2024.
The biotechnology company said the move is to allow use of fully GMP-grade raw materials in the vaccine, which is expected to increase the regulatory utility of the trial.
Gritstone said it decided to make the move after recent communication with the U.S. Food and Drug Administration and the Biomedical Advanced Research and Development Authority.
This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority.
Write to Chris Wack at [email protected]
Read the full article here
